Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
Vivek Narayan, Naomi Balzer Haas Division of Hematology/Medical Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-03-01
|
| Series: | International Journal of Nephrology and Renovascular Disease |
| Subjects: | |
| Online Access: | https://www.dovepress.com/axitinib-in-the-treatment-of-renal-cell-carcinoma-patient-selection-an-peer-reviewed-article-IJNRD |